Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Neoplasms | 3 |
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
ASO | 1 |
Target |
Mechanism KDM4D inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Aug 2024 |
Sponsor / Collaborator |
Start Date08 May 2023 |
Sponsor / Collaborator |
Start Date15 Jul 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
4-HB | Vancomycin-resistant enterococcal infection More | Preclinical |
KDM4D inhibitor (Yunnan University) ( KDM4D ) | Neoplasms More | Preclinical |
C069004 | Atherosclerosis More | Preclinical |
C069002 | Atherosclerosis More | Preclinical |
CN115160285 ( ALDH2 )Patent Mining | Neoplasms More | Discovery |